Table 1. Characteristics of studies... | American Society of Hematology

Table 1.

Characteristics of studies reporting maternal HLA-DRB3*01:01 carrier status in HPA-1a-immunized women and controls

First author, y^Reference	Country	No. of HPA-1a-immunized women		No. of nonimmunized controls*
First author, y^Reference	Country	No. of HLA-DRB3*01:01⁺	No. of HLA-DRB3*01:01⁻	No. of HLA-DRB3*01:01⁺	No. of HLA-DRB3*01:01⁻
Prospective studies
Williamson, 1998³⁵	United Kingdom	43	1	80	261
Maslanka, 2003²⁹	Poland	12	0	29†	71†
Turner, 2005³²	United Kingdom	18	7	89	189
Retrospective studies
Valentin, 1990³³	France	18	0	6	4
L'Abbé, 1992²⁷	Canada	32	3	3	7
Braud, 1994¹⁹	France	51	1	32	147
Loewenthal, 2013²⁸	Israel	20	3	2	22
Delbos, 2016²¹	France	38	7	33	67
Wienzek-Lischka, 2017³⁴	Germany	99	2	23	77

First author, y^Reference	Country	No. of HPA-1a-immunized women		No. of nonimmunized controls*
First author, y^Reference	Country	No. of HLA-DRB3*01:01⁺	No. of HLA-DRB3*01:01⁻	No. of HLA-DRB3*01:01⁺	No. of HLA-DRB3*01:01⁻
Prospective studies
Williamson, 1998³⁵	United Kingdom	43	1	80	261
Maslanka, 2003²⁹	Poland	12	0	29†	71†
Turner, 2005³²	United Kingdom	18	7	89	189
Retrospective studies
Valentin, 1990³³	France	18	0	6	4
L'Abbé, 1992²⁷	Canada	32	3	3	7
Braud, 1994¹⁹	France	51	1	32	147
Loewenthal, 2013²⁸	Israel	20	3	2	22
Delbos, 2016²¹	France	38	7	33	67
Wienzek-Lischka, 2017³⁴	Germany	99	2	23	77

Control groups were different for the prospective studies and retrospective studies; see text.

†

These figures were not reported, but were calculated from the positive and negative predictive values that were provided in the paper. For details, see supplemental Information regarding study.²⁹

View Large

This Feature Is Available To Subscribers Only